Dr Konstantinos Tzelepis

University of Cambridge

University departments
Wellcome Trust MRC Cambridge Stem Cell Institute
Milner Therapeutics Institute

Position: Group Leader
Personal home page:
Email:   kt404@cam.ac.uk

PubMed journal articles - click here

Research description
Our group is uncovering epigenetic and epitranscriptomic mechanisms that are implicated in cancer initiation and maintenance. Our work has previously identified several novel RNA-binding/modifying proteins that are essential for cancer cell survival, including the RNA methyltransferases METTL3 and METTL1 as well as the splicing kinase SRPK1. 
Research Programme or Virtual Institute
Haematological Malignancies Virtual Institute
Strategic Resources
The Milner Therapeutics Institute and Consortium
Tumour type interests
Brain and central nervous system
Small intestine

CRISPR Mutagenesis

Genetic Screening

Novel Therapeutics

Technology Development

Key publications
  1. Yankova, Blackaby et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021 
  2. Orellana et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell 2021
  3. Mikutis et al. meCLICK-Seq – a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Science 2020